The role of ATP-binding cassette transporters in the urinary excretion of diuretics was investigated. Significant ATPdependent uptake of hydrochlorothiazide (HCT) and furosemide was observed in membrane vesicles that expressed multidrug resistance-associated protein 4 (MRP4) and breast cancer resistance protein (BCRP). Unlike taurocholate uptake, S-methylglutathione had no effect on the ATP-dependent uptake of both compounds by MRP4. The functional importance of MRP4 and BCRP in the urinary excretion of HCT and furosemide was investigated using gene knockout mice. The renal clearance of HCT and furosemide was reduced significantly but not abolished in Mrp4 knockout mice compared with wild-type mice (9.0 ؎ 0.9 versus 15 ؎ 2 ml/min per kg for HCT and 1.9 ؎ 0.3 versus 2.7 ؎ 0.1 ml/min per kg for furosemide), and the amount of HCT that was associated with the kidney specimens was greater in Mrp4 knockout mice (21 ؎ 3 versus 13 ؎ 1 nmol/g kidney). In contrast, Bcrp makes only a negligible contribution because the urinary excretion was unchanged in Bcrp knockout mice. Our results suggest that Mrp4, together with other unknown transporters, accounts for the luminal efflux of HCT and furosemide from proximal tubular epithelial cells.
T he kidney plays important roles in the elimination of endogenous waste and xenobiotics and their metabolites. Urinary excretion is the major detoxification mechanism in the kidney, and this is governed by glomerular filtration, tubular secretion across the proximal tubules, and reabsorption. It is widely accepted that the renal secretion of drugs with anionic or cationic moieties across the renal tubules is achieved by cooperation between the uptake transporter at the basolateral membrane and the efflux transporter at the brush border membrane (BBM) (1) (2) (3) (4) .
Loop diuretics and thiazides are actively secreted from blood to the lumen by organic anion transport systems and exhibit diuretic effects by inhibiting the reabsorption of ions that are mediated by Na ϩ -K ϩ -2Cl Ϫ co-transporter in the loop of Henle and Na ϩ -Cl Ϫ co-transporter in the distal tubule from the luminal side, respectively (5) . In fact, co-administration of probenecid, a nonspecific inhibitor of organic anion transport systems, inhibits the renal elimination and diuretic action in humans (6, 7) . Two organic anion transporters play important roles in the basolateral uptake of organic anions. Organic anion transporter 1 (OAT1/SLC22A6) and OAT3 (SLC22A8) have broad substrate specificities, and kinetic analyses using rat kidney slices have suggested that Oat1 mainly is responsible for the renal uptake of hydrophilic and small organic anions, whereas Oat3 is responsible for the uptake of more bulky organic anions (8 -10) . Diuretics interact with OAT1 and OAT3, and, particularly, loop diuretics such as furosemide and bumetanide are substrates of OAT (11, 12) . Recently, Oat1 knockout mice were generated, and it was demonstrated that Oat1 was responsible for the renal uptake and pharmacologic action of furosemide (13) . However, an apical efflux mechanism for diuretics has not been reported yet.
Previous studies using BBM vesicles have suggested that the luminal transport of organic anions is composed of two distinct systems: (1) Electroneutral exchange of organic anions and (2) voltage-driven facilitated transport (14 -16) . In addition, immunohistochemical staining has demonstrated the expression of ATP-binding cassette (ABC) transporters, such as multidrug resistance-associated protein 2 (MRP2/ABCC2) and 4 (MRP4/ ABCC4), in the BBM of the proximal tubules of human and rodent kidney (17, 18) , whereas breast cancer resistance protein (BCRP/ABCG2) is found only in mouse kidney (19) . Because the substrate specificities of these ABC transporters are very broad (20 -22) , localization of ABC transporters along the BBM of the proximal tubules has led to considerable interest in their role in the urinary excretion of drugs. Because BBM vesicles that are prepared from the kidney predominantly are rightside-out oriented (23, 24) , they cannot be used for the detection of ATP-dependent uptake. In vivo pharmacokinetic studies using gene-deficient or knockout animals are necessary to obtain direct evidence regarding any involvement of ABC transporters in the luminal efflux of drugs.
In this study, we focused on MRP4 and BCRP. Both transporters accept a variety of organic anions as substrates, such as p-aminohippurate (PAH), 17␤-estradiol-17␤-d-glucuronide, dehydroepiandrosterone sulfate (DHEAS), and methotrexate (18, (25) (26) (27) . van Aubel et al. (18) initially found that Mrp4 is localized on the BBM, and, subsequently, Mrp4 was suggested to play important roles in tubular secretion (18, 25, 28) , although direct evidence of this still is lacking. For BCRP, an in vivo study using Bcrp knockout mice has demonstrated that BCRP is responsible for the urinary excretion of some organic anions, such as methotrexate and 6-hydroxy-5,7-dimethyl-2-methylamino-4-(3-pyridylmethyl) benzothiazole (E3040) sulfate (29, 30) . In this study, the functional involvement of Mrp4 and Bcrp in the urinary excretion of hydrochlorothiazide (HCT) and furosemide was examined by comparing their in vivo pharmacokinetics using their corresponding gene knockout mice. 
Materials and Methods

Membrane Vesicle Study
Membrane vesicles were prepared from recombinant adenovirus that contained human MRP4-infected (10 multiplicity of infection [MOI] ) and BCRP-infected (2 MOI) HEK293 cells that were derived from human embryonic kidney as described previously (26) . As negative controls, cells were infected with a virus that contained green fluorescence protein (GFP) cDNA (10 MOI). All of these recombinant adenoviruses had been established previously (26) . Membrane vesicles were isolated by the hypotonic method described previously in detail (26) . 
S-methyl-GSH, S-methylglutathione.
They finally were frozen in liquid nitrogen and stored at Ϫ80°C until required.
Transport studies were performed using a rapid filtration technique (26) . For the inhibition study, the amount of protein of each membrane vesicle that was used for each point was 3 g. A 0.45-m nitrocellulose membrane filter (Millipore Corp., Bedford, MA) was used for filtration of the stopped reaction mixture. Radioactivity that was retained on the filter was determined in a liquid scintillation counter (LS 6000SE; Beckman Instruments, Fullerton, CA). For the uptake of HCT and furosemide, 20 g of protein was used for each point. Substrates that were retained on the membrane filter (JH filter; Millipore) were dissolved in 1 ml of methanol that contained internal standard (benzthiazide) by sonication for 15 min. After centrifugation, supernatants were concentrated by centrifugal concentrator (CC-105; TOMY, Tokyo, Japan) and dissolved in 75 l of 10 mM ammonium acetate (pH 3.5 adjusted by HCOOH) plus acetonitrile at the ratio of 95 to 5. Then, 50-l aliquots were used for liquid chromatography/mass spectrometry (LC/MS) quantification as described below. The uptake activity was defined as the amount of ligand that was associated with the membrane vesicles divided by the ligand concentration in the transport buffer.
Western Blotting
Western blotting was performed as described previously (8) . ECL advance Western blotting Detection reagent (Amersham Pharmacia Biotech, Buckinghamshire, UK) was used for detection. Secondary antibody was labeled horseradish peroxidase (HRP), and HRP that was present on a Western blot was detected using a luminescence analyzer (LAS-3000 mini; Fuji Film Corp., Tokyo, Japan) to evaluate the chemiluminescence generated by the reaction of HRP with its substrate. The dilution of the primary antibodies were as follows: Polyclonal anti-MRP4 rabbit serum (Kamiya Biomedical Co., Seattle, WA), 1:1000; and monoclonal anti-BCRP (BXP-21; Kamiya Biomedical Co.), 1:200.
In Vivo Pharmacokinetic Analysis
After anesthesia with intraperitoneal sodium pentobarbital (50 mg/kg), the bladder was catheterized for urine collection. After an intravenous bolus injection (furosemide 800 nmol/kg; HCT 600 nmol/kg), furosemide (20 nmol/min per kg) and HCT (83 nmol/min per kg) were infused via the jugular vein. Blood samples were collected via the jugular vein at 30, 60, and 90 min after administration and centrifuged. Urine was collected at 0 to 30, 30 to 60, and 60 to 90 min. At the end of the experiment, kidneys were removed. For determination of the GFR, [ 3 H]inulin (0.4 mg; 0.9 Ci/min per kg) was infused via the jugular vein. Blood and urine samples were collected in the same way as for HCT and furosemide.
LC/MS Analysis
The quantification of HCT and furosemide was performed using and HPLC (HPLC, Alliance 2690; Waters, Milford, MA) connected to a mass spectrometer (ZQ; Micromass, Manchester, UK). Ten microliters of plasma, 2 l of urine, and 20 l of 33% (wt/vol) kidney homogenate was precipitated with 50 l (for plasma and urine sample) or 100 l (for kidney samples) of methanol that contained an internal standard (benzthiazide), mixed, and centrifuged, and then 45 l (for plasma and urine) or 90 l (for kidney) of the supernatants was concentrated by centrifugal concentrator (CC-105; TOMY, Tokyo, Japan). Concentrated samples were dissolved in 75 l of 10 mM ammonium acetate (pH 3.5 adjusted by HCOOH) plus acetonitrile at the ratio of 95 to 5, and 50-l aliquots were injected into the LC/MS. HPLC analysis was performed on a CAPCELL PAK C18 column (MGII, 3 m, 2.0 mm ID, 50 mm; Shiseido, Tokyo, Japan) at 40°C. Elution was performed with a 95 to 25% linear gradient of 10 mM ammonium acetate (pH 3.5 adjusted by HCOOH) over 5 min at 0.4 ml/min. The eluate was introduced into the MS via an electrospray interface. Detection was performed by selected ionization monitoring in negative ion mode (m/z 285, 296, and 430 for furosemide, HCT, and benzthiazide, respectively).
Pharmacokinetic Analysis
The renal clearance with respect to the plasma concentration (CL renal, p ) of furosemide in Mrp4 knockout mice was calculated using the following equation because the plasma concentration did not reach steady-state: area under the plasma concentration curve from 30 to 90 min (nmol ϫ min per ml), respectively.
Total body clearance of HCT (CL total ), CL renal, p , renal clearance with respect to the kidney concentration (CL renal, k ), and fractional urinary excretion (F urine ) were calculated from the following equations:
) ϫ 100 where I, C p , V urine , f p , and C k represent the infusion rate (nmol/min per kg), plasma concentration at 90 min (M), urinary excretion rate from 60 to 90 min (nmol/min per kg), and plasma unbound fraction and kidney concentration at 90 min (M), respectively. C k is the drug concentrations in the kidney (M), estimated as the amount of diuretics in the kidney (nmol/g kidney assuming that 1 g of kidney ϭ 1 ml). GFR was determined in a separate experiment and calculated from the urinary excretion rate of f p ϭ (C filtrate /C plasma )/R where C filtrate , C plasma , and R are the filtrate concentration, plasma concentration, and recovery rate, respectively. Drug recovery using PBS solution was determined to correct for membrane adsorption. The recovery rate of furosemide and HCT was 0.94 and 0.95, respectively.
Statistical Analyses
Statistical analysis was performed by t test (in vivo study and uptake study using membrane vesicles [ Figures 1C and 2] ) or ANOVA followed by Dunnett test (inhibition study using membrane vesicles [ Figure 1D] ) to identify significant differences between two sets of data.
Results
Characterization of Membrane Vesicles and Effects of Diuretics on MRP4-and BCRP-Mediated Transport
The expression of MRP4 and BCRP proteins in membrane vesicles were confirmed by Western blotting (Figure 1, A Figure 3 and the equations described in Materials and Methods. Data are means Ϯ SEM (n ϭ 4). CL total , total body clearance; CL renal, p , renal clearance with respect to the concentration in circulating plasma; CL renal, k , renal clearance with respect to the kidney concentration; C kidney , drug concentration in the kidney at 90 min; V urine , urinary excretion rate; F urine , fractional urinary excretion; K p , kidney to plasma concentration ratio; f p , plasma unbound fraction.
b P Ͻ 0.05. c P Ͻ 0.01. a Furosemide was infused intravenously for 90 min. Each value was determined from the data shown in Figure 3 and the equations described in Materials and Methods. CL total of Mrp4 knockout mice was not determined because the plasma concentration did not reach steady state as shown in Figure 3C . Data are means Ϯ SEM (n ϭ 4). CL total , total body clearance; AUC 30 to 90 min, area under the plasma concentration curve from 30 to 90 min; X urine 30 to 90 min, urinary excretion mass from 30 to 90 min.
b P Ͻ 0.05. Figure 1C ). The effects of diuretics on ATP-dependent uptake by MRP4-and BCRP-expressing membrane vesicles were examined ( Figure 1D ). All of the tested diuretics inhibited MRP4-mediated transport of [ 3 H]DHEAS, whereas those other than HCT inhibited BCRP-mediated transport of [ 3 H]E 1 S. HCT rather enhanced BCRP-mediated transport. Furosemide is a potent inhibitor of MRP4 (IC 50 10 M), whereas bumetanide and ethacrynic acid are moderate inhibitors (IC 50 10 to 100 M), and the others are only weak inhibitors (IC 50 Ͼ500 M). Furosemide, ethacrynic acid, and trichlormethiazide inhibited BCRP with a similar potency as that of MRP4. Bumetanide is a weaker inhibitor of BCRP than MRP4 (IC 50 100 to 1000 M), whereas acetazolamide is a more potent inhibitor of BCRP than MRP4.
ATP-Dependent Transport of HCT and Furosemide by MRP4-and BCRP-Expressing Membrane Vesicles
The uptake of HCT and furosemide by MRP4-and BCRPexpressing membrane vesicles was determined ( Figure 2, A and  B) . ATP-dependent uptake of HCT was observed only in MRP4-and BCRP-expressing membrane vesicles but not in GFP-expressing vesicles (Figure 2A) . Although the uptake of furosemide also was stimulated in the presence of ATP both in MRP4-and BCRP-expressing and GFP-expressing vesicles, the level and the degree of stimulation were greater in MRP4-and BCRP-expressing membrane vesicles than that in GFP-expressing vesicles ( Figure 2B ). Glutathione has been reported to stimulate the ATP-dependent uptake of taurocholate by MRP4 (32). However, the stimulatory effect was not observed for HCT and furosemide ( Figure 2, C and D) .
Renal Excretion of HCT and Furosemide in Mrp4 Knockout and Wild-Type Mice
As summarized in Table 1 , the physiologic parameters, such as body weight, urine volume, and GFR, were comparable in Mrp4 knockout and wild-type mice. HCT was given by intravenous infusion. Although the plasma concentration was similar in Mrp4 knockout and wild-type mice ( Figure 3A) , the urinary excretion rate was significantly reduced at 90 min in Mrp4 knockout mice compared with wild-type mice ( Figure  3B ). The HCT concentration in the kidney was greater in Mrp4 knockout mice than that in wild-type mice. The pharmacokinetic parameters are summarized in Table 2 . CL renal, p and CL renal, k were reduced significantly in Mrp4 knockout mice (Table 2 ), although CL total was similar in the two strains. The f p of HCT in BL6J mice was 0.38 Ϯ 0.03.
Furosemide also was given by intravenous infusion. The concentrations of furosemide in plasma and urine were determined in Mrp4 knockout and wild-type mice. The urinary excretion rate was lower in Mrp4 knockout mice than in wildtype mice ( Figure 3D ). The pharmacokinetic parameters are summarized in Table 3 . The CL renal, p was reduced significantly in Mrp4 knockout mice compared with wild-type mice ( Table  3 ). The f p of furosemide in C57BL/6J mice was 0.0054 Ϯ 0.0011.
Renal Excretion of HCT and Furosemide in Bcrp Knockout and Wild-Type Mice
The plasma concentrations and urinary excretion rates after intravenous infusion of HCT and furosemide in Bcrp knockout mice and wild-type mice are shown in Figure 4 , and the pharmacokinetic parameters are summarized in Table 4 . Knockout of Bcrp did not affect the pharmacokinetic profiles of HCT and furosemide ( Figure 4, Table 4 ).
Discussion
In this study, we have demonstrated that HCT and furosemide are substrates of MRP4 and BCRP using membrane vesicles, and in vivo studies using gene knockout mice were carried out to examine whether Mrp4 and Bcrp play significant roles in the urinary excretion of furosemide and HCT. In the transport studies using membrane vesicles, we found that diuretics, such as loop diuretics, thiazides, and carbonic anhydrase inhibitors, are inhibitors of MRP4 and BCRP, whereas HCT stimulated BCRP-mediated transport ( Figure 1D ). Furosemide, ethacrynic acid, and trichloromethiazide had a similar inhibitory effect on MRP4 and BCRP. In particular, loop diuretics were potent inhibitors of MRP4 and BCRP. In further analysis, it was found that both HCT and furosemide were substrates of MRP4 and BCRP, and furosemide exhibited markedly greater transport activities than HCT (Figure 2, A and B) . The transport activities of HCT and furosemide were similar for MRP4 and BCRP. Rius et al. (32) demonstrated that the ATP- The renal clearance of HCT and furosemide was determined in wild-type and Mrp4 knockout mice. Taking their plasma unbound fractions and GFR into consideration, the renal clearance of HCT and furosemide is accounted for mainly by tubular secretion. Although the total clearance exhibited no change, the renal clearance with respect to the plasma concentration of HCT was lower in Mrp4 knockout mice than that in wild-type mice, approximately 60% of the control value (Table 2) . Because the K p value was increased 1.7-fold in Mrp4 knockout mice (Table 2) , the intrinsic clearance of the luminal efflux was reduced to 45% of the control value in Mrp4 knockout mice. The discrepancy between the total body clearance and renal clearance can be explained by introduction of the concept of a rate-limiting process. In the case in which the luminal efflux clearance is significantly greater than the efflux clearance of the basolateral side, the uptake process becomes a rate-limiting one for the elimination of drugs from the plasma, and a reduction in the luminal efflux clearance hardly affects the plasma concentration-time profile (illustrated in Figure 5 ). The increased kidney concentration that is produced by knockout of Mrp4 indicates that the efflux that is mediated by Mrp4 makes a significant contribution to the total efflux from inside the cells and supports this speculation. For furosemide, the renal clearance with respect to the plasma concentration was reduced in Mrp4 knockout mice to approximately 70% of that in wild-type mice (Table 3) . Because the plasma concentration did not reach steady state, even after a 90-min infusion, the intrinsic parameter governing the luminal efflux could not be obtained. Prolongation of the plasma half-life in Mrp4 knockout mice as a result of reduced total body clearance may affect the duration time in the body. These results suggest that Mrp4 accounts for part of the tubular secretion of HCT and furosemide at the BBM side in concert with OAT ( Figure 5) .
The renal clearance of HCT and furosemide in Mrp4 knockout mice still was greater than their GFR (f p ϫ GFR; Tables 2  and 3) , suggesting the involvement of other efflux transporters. In contrast to Mrp4 knockout mice, there was no significant difference in the urinary excretion of HCT and furosemide between Bcrp knockout and wild-type mice (Table 4) . This excludes the involvement of Bcrp, although the transport activities of HCT and furosemide are similar for MRP4 and BCRP in membrane vesicles (Figure 2, A and B) .
Reduced MRP4 activity may be associated with a prolonga- Figure 4 and the equations described in Materials and Methods. Each value represents the mean Ϯ SEM (n ϭ 4). Bcrp, breast cancer resistance protein.
. Figure 5 . Schematic diagram illustrating the tubular secretion mechanisms of HCT and furosemide. After furosemide and HCT are taken up by organic anion transporter 1 (OAT1) and/or OAT3 into the renal tubular cells, MRP4 and unknown transporters are responsible for the luminal efflux. BCRP makes only a minor contribution. It is likely that luminal efflux clearance of HCT and furosemide is greater than the efflux clearance at the basolateral side. Under this condition, the uptake process at the basolateral side becomes a rate-limiting step for the elimination of drugs from the plasma, and reduction of luminal efflux as a result of knockout of Mrp4 hardly affects the plasma elimination clearance. NaDC, sodium-dicarboxylate co-transporter.
tion of the plasma elimination half-life and may increase concomitantly the kidney concentration more than expected from the increased plasma concentration. Generally, accumulation of drugs in the kidney can be associated with nephrotoxicity, and, particularly, the plasma concentration cannot be a predictor of adverse effects when the uptake process is rate limiting. MRP4 confers resistance to adefovir and cidofovir (antiviral drugs) (33) . These drugs are actively secreted into the urine, and one of their adverse effects is severe nephrotoxicity (34) . Because the expression of MRP4 overcomes the cytotoxicity of adefovir in HEK293 cells (35) , it is possible that MRP4 activity is related to their renal toxicity through the regulation of their tissue concentration. The factors that potentially cause a functional change in MRP4 include pathophysiologic conditions, aging, and genetic polymorphisms or mutations. Of these factors, Denk et al. (36) found that the Mrp4 protein in the kidneys fell markedly 14 d after common bile duct ligation. Cholestasis may increase the risk for drug-induced nephrotoxicity.
Conclusion
We have demonstrated that Mrp4 accounts, at least in part, for the urinary excretion of HCT and furosemide. Our findings illustrate, for the first time, the role of MRP4 in the urinary excretion of drugs in concert with basolateral organic anion transporters. This finding will contribute to a better understanding of the urinary excretion mechanisms of drugs and the factors that are associated with their nephrotoxicity.
